Comparative Pharmacology
Head-to-head clinical analysis: LONSURF versus SYNRIBO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONSURF versus SYNRIBO.
LONSURF vs SYNRIBO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Omacetaxine mepesuccinate inhibits protein synthesis by binding to the ribosomal A-site and preventing aminoacyl-tRNA binding, thereby inhibiting peptide elongation. It also induces apoptosis in leukemic cells.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
1.25 mg/m2 subcutaneously twice daily for 14 consecutive days, followed by 7 days rest (21-day cycle).
None Documented
None Documented
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Terminal half-life approximately 9.3 ± 7.0 hours; clinical context: once-daily subcutaneous dosing maintains steady-state concentrations.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Primarily fecal (80%) and renal (20%) as unchanged drug, with negligible metabolism.
Category C
Category C
Antineoplastic
Antineoplastic